The systematic review by Liyun He et al. also found that the use of GLP-1 RAs was associated with an increased risk of cholelithiasis (RR 1.27; 95% CI 1.10–1.47), cholecystitis (RR 1.36; 95% CI 1.14–1.62), and biliary diseases (RR 1.55; 95% CI 1.08–2.22) (He et al., 2022b). This evidence concerns the gene GLP1R and Cholecystitis.